Posted in:News Genentech Files Suit Alleging Eli Lilly’s Taltz® Product Infringes a Newly Issued Genentech Patent By Seth Cockrum July 16, 2018 Comments are off On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s... Read more Tagged with: Eli Lilly, Genentech, ixekizumab, News, Taltz® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Genentech Files Two New Lawsuits Against Celltrion Alleging Infringement of Patents Related to Rituxan® and Herceptin® By Seth Cockrum July 12, 2018 Comments are off As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents... Read more Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, News, Patent Dance, Rituxan®, Rituximab, trastuzumab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News U.S. FDA Approves First Biosimilar to Neulasta By Andrew Storaska June 29, 2018 Comments are off Earlier this month, the U.S. FDA announced approval of Mylan’s Fulphila biosimilar to Neulasta® (pegfilgrastim). Neulasta® was... Read more Tagged with: Amgen, Biocon, EMA, FDA, Fulphila, Mylan, Neulasta®, pegfilgrastim http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News PTAB Denies Another IPR Petition Relating to Adalimumab By Nicole DeAbrantes June 14, 2018 Comments are off The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of... Read more Tagged with: AbbVie, adalimumab, IPR, News, PTAB, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches By Seth Cockrum May 25, 2018 Comments are off Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, eptinezumab, erenumab, FDA, fremanezumab, galcanezumab, News, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Novartis and Amgen Announce FDA Approval of Aimovig™ By Seth Cockrum May 23, 2018 Comments are off Last week, Novartis and Amgen announced the FDA approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. The... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, erenumab, FDA, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Seeks Joinder with Pfizer IPR Challenging Rituximab-Related Patent By Seth Cockrum May 18, 2018 Comments are off Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838... Read more Tagged with: Boehringer Ingelheim, Celltrion, IPR, News, Pfizer, PTAB, Rituximab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus